Equity Profile

CNTA

Centessa Pharmaceuticals plc

Health CareBiotechnology$6.3B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Centessa Pharmaceuticals plc is a biotechnology company focused on developing innovative therapies to address unmet medical needs. Operating in the healthcare sector, it plays a vital role in advancing drug development and improving patient outcomes.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and generate sales from its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CNTA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q1-2026, Centessa reported an EPS of -$0.52, missing estimates by a significant margin. The stock reacted with a slight decline of 0.08% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Centessa's upcoming earnings, given the company's focus on innovative therapies. However, the lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Centessa can show improved financial metrics and progress in its drug development pipeline, it could lead to a positive market reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations and fails to provide clear guidance, it may face significant downward pressure on its stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's recent performance, a clear EPS figure will be crucial for gauging financial health and market confidence.

What progress has been made in the drug development pipeline?

Updates on the pipeline can significantly influence investor sentiment and expectations for future revenue growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Centessa's pipeline to deliver significant advancements, which could lead to better-than-expected results.

Supporting Evidence

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Past performance shows that even with misses, the stock has sometimes reacted positively, suggesting potential for recovery.

Key Risk

If the EPS comes in better than -$0.50, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching EPS and pipeline developments as indicators of Centessa's future potential.

Bull Confirmed If

A reported EPS improvement to -$0.30 or better would confirm the bull case.

Bear Confirmed If

An EPS of -$0.60 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.42%

Historical Avg

±8.2%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±17.4% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

2.5%

Calls (5K)P/C Ratio: 27.83Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations, history suggests the stock could rise by around 0.04%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess.

Miss

A miss could lead to a decline of around 8.63%, reflecting ongoing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on key drug candidates in the pipeline.
2Details on cost management and operational efficiency.
3Insights into market demand for their therapies.
4Management's outlook on future revenue streams.
5Responses to analyst questions regarding recent performance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and generate sales from its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CNTA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q1-2026, Centessa reported an EPS of -$0.52, missing estimates by a significant margin. The stock reacted with a slight decline of 0.08% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Centessa's upcoming earnings, given the company's focus on innovative therapies. However, the lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Centessa can show improved financial metrics and progress in its drug development pipeline, it could lead to a positive market reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations and fails to provide clear guidance, it may face significant downward pressure on its stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's recent performance, a clear EPS figure will be crucial for gauging financial health and market confidence.

What progress has been made in the drug development pipeline?

Updates on the pipeline can significantly influence investor sentiment and expectations for future revenue growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Centessa's pipeline to deliver significant advancements, which could lead to better-than-expected results.

Supporting Evidence

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Past performance shows that even with misses, the stock has sometimes reacted positively, suggesting potential for recovery.

Key Risk

If the EPS comes in better than -$0.50, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching EPS and pipeline developments as indicators of Centessa's future potential.

Bull Confirmed If

A reported EPS improvement to -$0.30 or better would confirm the bull case.

Bear Confirmed If

An EPS of -$0.60 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.42%

Historical Avg

±8.2%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±17.4% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

2.5%

Calls (5K)P/C Ratio: 27.83Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations, history suggests the stock could rise by around 0.04%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess.

Miss

A miss could lead to a decline of around 8.63%, reflecting ongoing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on key drug candidates in the pipeline.
2Details on cost management and operational efficiency.
3Insights into market demand for their therapies.
4Management's outlook on future revenue streams.
5Responses to analyst questions regarding recent performance.